Vascular remodeling in pulmonary hypertension

Journal of Molecular Medicine

Volumn 91, Issue 3, 2013, Pages 297-309

  Shimoda, Larissa A ^a   Laurie, Steven S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Pulmonary arterial pressure; Pulmonary hypertension; Pulmonary vascular resistance; Vascular remodeling

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM ION; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1; MONOCROTALINE; POTASSIUM CHANNEL; RHO KINASE; SEROTONIN; SEROTONIN TRANSPORTER; SILDENAFIL; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTERY MUSCLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; FOLLOW UP; GENE MUTATION; HUMAN; HYPOXIA; NONHUMAN; PH; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIUM;

ANIMALS; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1; MICE; PULMONARY ARTERY; RATS; RHO-ASSOCIATED KINASES; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 84875708891     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-0998-0     Document Type: Review

References (160)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537
2. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55-S66
3. Voelkel NF, Tuder RM (2000) Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest 106:733-738
4. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297:L1013-L1032
5. Tuder RM (2009) Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 30:376-385
6. Stenmark KR, Rabinovitch M (2010) Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med 11:S85-S90
7. Gan CT-J, Lankhaar J-W, Westerhof N, Marcus JT, Becker A, Twisk JWR, Boonstra A, Postmus PE, Vonk-Noordegraaf A (2007) Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 132(6):1906-1912
8. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD (2006) Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 47:799-803
9. Vanderpool RR, Kim AR, Molthen R, Chesler NC (2011) Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function. J Appl Physiol 110:188-198
10. Hyvelin J-M, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P (2005) Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97:185-191
11. Stenmark KR, McMurtry IF (2005) Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal? Circ Res 97:95-98
12. McMurtry IV, Abe K, Ota H, Fagan KA, Oka M (2010) Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 661:299-308
13. Penaloza D, Arias-Stella J, Sime F, Recavarren S, Marticorena E (1964) The heart and pulmonary circulation in children at high altitudes: physiological, anatomical, and clinical observations. Pediatrics 34:568-582
14. Rotta A, Canepa A, Hurtado A, Velasquez T, Chavez R (1956) Pulmonary circulation at sea level and at high altitudes. J Appl Physiol 9:328-336
15. Pryor R, Weaver WF, Blount SG (1965) Electrocardiographic observation of 493 residents living at high altitude (10,150 feet). Am J Cardiol 16:494-499
16. Naeye RL (1961) Hypoxemia and pulmonary hypertension. A study of the pulmonary vasculature. Arch Pathol 71:447-452
17. Naeye RL (1965) Children at high altitude: pulmonary and renal abnormalities. Circ Res 16:33-38
18. Arias-Stella J, Saldana M (1963) The terminal portion of the pulmonary arterial tree in people native to high altitudes. Circulation 28:915-925
19. Heath D, Smith P, Rios Dalenz J, Williams D, Harris P (1981) Small pulmonary arteries in some natives of La Paz, Bolivia. Thorax 36:599-604
20. Groves BM, Droma T, Sutton JR, McCullough RG, McCullough RE, Zhuang J, Rapmund G, Sun S, Janes C, Moore LG (1993) Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol 74:312-318
21. Gupta ML, Rao KS, Anand IS, Banerjee AK, Boparai MS (1992) Lack of smooth muscle in the small pulmonary arteries of the native Ladakhi. Is the Himalayan highlander adapted? Am Rev Respir Dis 145:1201-1204
22. Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P (1988) A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med 66:65-85
23. Barberà JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, Wiggs BR, Rodriguez-Roisin R (1994) Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 149:423-429
24. Wright JL, Petty T, Thurlbeck WM (1992) Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 170:109-124
25. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, Barberà JA (2002) Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 19:632-638
26. Voelkel N, Mizuno S, Gomez-Arroyo J (2011) COPD/emphysema: the vascular story. Pulm Circ 3:320
27. Glover GH, Newsom IE (1915) Brisket disease: dropsy of high altitudes. Colo Agric Exp Station 204:3-24
28. Rhodes J (2005) Comparative physiology of hypoxic pulmonary hypertension: historical clues from brisket disease. J Appl Physiol 98:1092-1100
29. Stenmark KR, Fasules J, Hyde DM, Voelkel NF, Henson J, Tucker A, Wilson H, Reeves JT (1987) Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4,300 m. J Appl Physiol 62:821-830
30. Rabinovitch M, Gamble WJ, Nadas AS, Miettinen OS, Reid L (1979) Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol 236:H818-H827
31. Rabinovitch M, Chesler N, Molthen RC (2007) Point:counterpoint: chronic hypoxia-induced pulmonary hypertension does/does not lead to loss of pulmonary vasculature. J Appl Physiol 103:1449-1451
32. Hislop A, Reid L (1976) New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br J Exp Pathol 57:542-554
33. Berg JT (2007) Chronic hypoxia-induced pulmonary hypertension does/does not lead to loss of pulmonary vasculature. J Appl Physiol 103:1455
34. Mcloughlin P, Mcmurtry I (2007) Counterpoint: chronic hypoxia-induced pulmonary hypertension does not lead to loss of pulmonary vasculature. J Appl Physiol 103:1451-1453, discussion 1453-1454
35. Howell K, Preston RJ, McLoughlin P (2003) Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol 547:133-145
36. Bauer NR, Moore TM, McMurtry IF (2007) Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 293:L580-L582
37. Paddenberg R, Stieger P, Von Lilien A-L, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC (2007) Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 8:15
38. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99:675-691
39. Jaenke RS, Alexander AF (1973) Fine structural alterations of bovine peripheral pulmonary arteries in hypoxia-induced hypertension. Am J Pathol 73:377-398
40. Nagaoka T, Muramatsu M, Sato K, McMurtry I, Oka M, Fukuchi Y (2001) Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 127:53-60
41. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ (1992) Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 145:793-797
42. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:427-438
43. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747-2754
44. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G et al (2012) A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 184:1171-1182
45. Kay JM, Harris P, Heath D (1967) Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 22:176-179
46. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D et al (2012) A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 302:L977-L991
47. Meyrick B, Gamble W, Reid L (1980) Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol 239:H692-H702
48. Tanaka Y, Schuster DP, Davis EC, Patterson GA, Botney MD (1996) The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J Clin Invest 98:434-442
49. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD (1997) Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151:1019-1025
50. Maclean MR, Dempsie Y (2010) The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol 661:309-322
51. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K (2000) Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130:201-204
52. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S (1999) Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res 84:329-336
53. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR (2011) The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 90:373-382
54. Lowery JW, de Caestecker MP (2010) BMP signaling in vascular development and disease. Cytokine Growth Factor Rev 21:287-298
55. Sieber C, Kopf J, Hiepen C, Knaus P (2009) Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20:343-355
56. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ et al (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737-744
57. Elliott CG (2005) Genetics of pulmonary arterial hypertension: current and future implications. Semin Respir Crit Care Med 26:365-371
58. Newman JH, Phillips JA, Loyd JE (2008) Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med 148:278-283
59. Davies RJ, Morrell NW (2008) Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 134:1271-1277
60. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD (2004) BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 287:L1241-L1247
61. Song Y, Jones JE, Beppu H, Keaney JF, Loscalzo J, Zhang Y-Y (2005) Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112:553-562
62. Frank DB, Lowery J, Anderson L, Brink M, Reese J, de Caestecker M (2008) Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 294:L98-L109
63. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R et al (2004) Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94:1109-1114
64. Suzuki H, Twarog BM (1982) Membrane properties of smooth muscle cells in pulmonary hypertensive rats. Am J Physiol 242:H907-H915
65. Shimoda LA, Polak J (2011) Theme: Hypoxia. Hypoxia and ion channel function. Am J Physiol Cell Physiol 300(5):C951-C967
66. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98:1400-1406
67. Burg ED, Remillard CV, Yuan JX (2008) Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol 153(Suppl 1):S99-S111
68. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL (2002) Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105:244-250
69. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS et al (2006) An abnormal mitochondrial-hypoxia inducible factor-1a-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113:2630-2641
70. + channel gene transcription in primary pulmonary hypertension. Lancet 351:726-727
71. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED (2007) The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 104:11418-11423
72. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107:2037-2044
73. i, and ET-1-induced responses in chronically hypoxic pulmonary myocytes. Am J Physiol Lung Cell Mol Physiol 279:L884-L894
74. 2+ in pulmonary arterial smooth muscle cells. Circ Res 98:1528-1537
75. 2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 95:496-505
76. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81
77. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111
78. Bonnet S, Dumas-de-La-Roque E, Begueret H, Marthan R, Fayon M, Dos Santos P, Savineau JP, Baulieu EE (2003) Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A 100:9488-9493
79. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830-840
80. 2+ entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol 280:H746-H755
81. Landsberg JW, Yuan JX (2004) Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol Sci 19:44-50
82. Leggett K, Maylor J, Undem C, Lai N, Lu W, Schweitzer KS, King LS, Myers AC, Sylvester JT, Sidhaye VK et al (2012) Hypoxia-induced migration in pulmonary arterial smooth muscle cells requires calcium-dependent upregulation of aquaporin 1. Am J Physiol Lung Cell Mol Physiol 303:L343-L353
83. 2+ entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Cell Physiol 302:C77-C87
84. Song MY, Makino A, Yuan JX (2011) STIM2 contributes to enhanced store-operated Ca entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Pulm Circ 1:84-94
85. 2+ channels by ET-1 in pulmonary arterial myocytes during chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 302:L1128-L1139
86. Hirenallur SD, Haworth ST, Leming JT, Chang J, Hernandez G, Gordon JB, Rusch NJ (2008) Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295:L915-L924
87. Rodman DM, Reese K, Harral J, Fouty B, Wu S, West J, Hoedt-Miller M, Tada Y, Li KX, Cool C et al (2005) Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 96:864-872
88. Hisatsune C, Kuroda Y, Nakamura K, Inoue T, Nakamura T, Michikawa T, Mizutani A, Mikoshiba K (2004) Regulation of TRPC6 channel activity by tyrosine phosphorylation. J Biol Chem 279:18887-18894
89. Odell AF, Scott JL, Van Helden DF (2005) EGF induces tyrosine phosphorylation, membrane insertion and activation of transient receptor potential channel 4. J Biol Chem 280:37974-37987
90. 2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. Am J Physiol Lung Cell Mol Physiol 293:L674-L685
91. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX (2004) Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 101:13861-13866
92. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, Yuan JX (2004) Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med 170:1101-1107
93. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang JY et al (2009) A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 119:2313-2322
94. Lu W, Ran P, Zhang D, Peng G, Li B, Zhong N, Wang J (2010) Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol 298:C114-C123
95. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105-113
96. Yang J, Li X, Al-Lamki R, Wu C, Weiss A, Berk J, Schermuly RT, Morrell NW (2013) Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 33:34-42
97. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P, Loirand G (2005) Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146:1010-1018
98. 2+ signaling. Am J Physiol Heart Circ Physiol 302:H1546-H1562
99. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU (2010) MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 299:L861-L871
100. Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, Kardassis D, Vasilaki E, Huang M, Mitchell JA, Harrington LS et al (2012) Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res 110:1423-1434
101. Martin E, Dahan D, Cardouat G, Gillibert-Duplantier J, Marthan R, Savineau JP, Ducret T (2012) Involvement of TRPV1 and TRPV4 channels in migration of rat pulmonary arterial smooth muscle cells. Pflugers Arch 464:261-272
102. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434:786-792
103. Monzani E, Bazzotti R, Perego C, La Porta CA (2009) AQP1 is not only a water channel: it contributes to cell migration through Lin7/beta-catenin. PLoS One 4:e6167
104. 2+ entry in human pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 285:L1233-L1245
105. 2+ entry in pulmonary endothelial cells from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 293:L1135-L1142
106. Madden JA, Ray DE, Keller PA, Kleinman JG (2001) Ion exchange activity in pulmonary artery smooth muscle cells: the response to hypoxia. Am J Physiol Lung Cell Mol Physiol 280:L264-L271
107. + exchange to pH regulation in pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 5:586-591
108. + exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 14:139-145
109. + exchange in pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 289(5):L867-L874
110. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 291:L941-L949
111. Quinn DA, Du HK, Thompson BT, Hales CA (1998) Amiloride analogs inhibit chronic hypoxic pulmonary hypertension. Am J Respir Crit Care Med 157:1263-1268
112. Yu L, Quinn DA, Garg HG, Hales CA (2008) Deficiency of the NHE1 gene prevents hypoxia-induced pulmonary hypertension and vascular remodeling. Am J Respir Crit Care Med 177:1276-1284
113. Yu L, Hales CA (2011) Silencing of NHE1 attenuates PASMC proliferation, hypertrophy and migration via E2F1. Am J Respir Cell Mol Biol 45:923-930
114. + antiport activity, isoform expression, and localization in endothelial cells. Am J Physiol 275:L442-L451
115. Phillips PG, Birnby LM, Narendran A (1995) Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells. Am J Physiol 268:L789-L800
116. + translocation. Mol Cell 6:1425-1436
117. + exchange regulatory factor 1 in hypoxic pulmonary arterial smooth muscle cells. FASEB J 24:1023.4, Abstract
118. Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, Haverich A, Knight J, Menasche P, Myers ML et al (2008) Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 85:1261-1270
119. Murphy E, Allen DG (2009) Why did the NHE inhibitor clinical trials fail? J Mol Cell Cardiol 46:137-141
120. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF (2007) Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100:923-929
121. Ward JPT, Mcmurtry IF (2009) Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem. Curr Opin Pharmacol 9:287-296
122. Firth AL, Choi I-W, Park WS (2012) Animal models of pulmonary hypertension: Rho kinase inhibition. Prog Biophys Mol Biol 109:67-75
123. Oka M, Fagan KA, Jones PL, McMurtry IF (2008) Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 155:444-454
124. Yang X, Lee PJ, Long L, Trembath RC, Morrell NW (2007) BMP4 induces HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary artery myocytes. Am J Respir Cell Mol Biol 37:598-605
125. Gerthoffer WT (2007) Mechanisms of vascular smooth muscle cell migration. Circ Res 100:607-621
126. Liu Y, Suzuki YJ, Day RM, Fanburg BL (2004) Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res 95:579-586
127. + exchange activity in murine pulmonary arterial smooth muscle cells via Rho kinase. PLoS One 7:e46303
128. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H (2005) Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391-392
129. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T (2006) Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70:174-178
130. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171:494-499
131. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Hear Vessel 25:144-149
132. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287:L656-L664
133. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K et al (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94:385-393
134. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda LA, Tuder RM, Johns RA, Hassoun PM (2007) Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 292:L1105-L1110
135. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC (2001) Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation 104:790-795
136. i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 299:C1370-C1378
137. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053-1063
138. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP, Chandler RL, de Caestecker MP (2010) Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 298:R833-R842
139. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP (2005) Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 97:496-504
140. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, Deutsch R, Jamieson SW, Thistlethwaite PA (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348:500-509
141. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M, Fukuchi Y (2006) Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290:L450-L458
142. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, Granton J, Stewart DJ (2006) Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res 98:209-217
143. Gangopahyay A, Oran M, Bauer EM, Wertz JW, Comhair SA, Erzurum SC, Bauer PM (2011) Bone morphogenetic protein receptor II is a novel mediator of endothelial nitric-oxide synthase activation. J Biol Chem 286:33134-33140
144. Hu H, Sung A, Zhao G, Shi L, Qiu D, Nishimura T, Kao PN (2006) Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun 339:59-64
145. 2+ channels. J Hypertens Suppl 6:S188-S191
146. Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 63:504-511
147. Shimoda LA, Sham JS, Liu Q, Sylvester JT (2002) Acute and chronic hypoxic pulmonary vasoconstriction: a central role for endothelin-1? Respir Physiol Neurobiol 132:93-106
148. + channel expression in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 294:L309-L318
149. Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA (2009) The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Investig 39(Suppl 2):38-49
150. Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM (2008) Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol 155:606-616
151. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447-5454
152. Semenza GL (2005) Pulmonary vascular responses to chronic hypoxia mediated by hypoxia-inducible factor 1. Proc Am Thorac Soc 2:68-70
153. Prabhakar NR, Semenza GL (2012) Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92:967-1003
154. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT et al (1999) Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest 103:691-696
155. Shimoda LA, Semenza GL (2011) HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 183:152-156
156. Shimoda LA (2012) 55th Bowditch lecture: effects of chronic hypoxia on the pulmonary circulation: role of HIF-1. J Appl Physiol 113:1343-1352
157. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12:149-162
158. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P (2003) Heterozygous deficiency of hypoxia-inducible factor-2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 111:1519-1527
159. Shimoda LA (2010) Hypoxic regulation of ion channels and transporters in pulmonary vascular smooth muscle. Adv Exp Med Biol 661:221-235
160. Abud EM, Maylor J, Undem C, Punjabi A, Zaiman AL, Myers AC, Sylvester JT, Semenza GL, Shimoda LA (2012) Digoxin inhibits development of hypoxic pulmonary hypertension in mice. Proc Natl Acad Sci U S A 109:1239-1244